Rabies immunoglobulin short supply

 2 December 2019

Rabies immunoglobulin (RIg) is one component of the post-exposure prophylaxis for people who may have been exposed to rabies virus or other lyssaviruses. RIg is in short supply globally and Australia has exhausted its supply of Imogam, the registered human RIg product.

An alternative human RIg product, KamRAB, has been sourced for use in Australia. KamRAB is not registered for use in Australia. It is approved under section 19A of the Therapeutic Goods Act 1989 until 31 January 2021.

Two information sheets have been developed to provide information about KamRAB and explain the risks and benefits:

Contact public health unit on 1300 066 055 for advice on post-exposure prophylaxis and to order RIg and rabies vaccine for patients who may have been exposed to rabies virus or other lyssaviruses.

Information about the administration of RIg, and who may need it is available from the Australian Immunisation Handbook​.

Further information: